Core Viewpoint - Garden Bio has received approval from the Ministry of Agriculture and Rural Affairs for its cholesterol derived from lanolin as a new feed additive, which is expected to enhance its product application areas and core competitiveness [1][2][3] Group 1: Product Approval and Market Potential - Cholesterol derived from lanolin has been approved as a new feed additive for shrimp, with a recommended addition rate of 1.0-2.0g/kg in feed and a maximum limit of 10g/kg [1] - The total industrial feed production in China is projected to reach 31,503.1 million tons in 2024, with aquaculture feed accounting for approximately 2,262 million tons, representing 7.18% of the total feed production [1] Group 2: Company Overview and Production Capacity - Garden Bio is primarily engaged in the research, production, and sales of vitamin D3 and A series products, with a focus on lanolin cholesterol, vitamin D3, and 25-hydroxy vitamin D3 [2] - The company has established itself as a global leader in the vitamin D3 production chain, with an annual production capacity of 3,600 tons, making it one of the largest vitamin D3 producers globally [3] - The annual production of NF-grade cholesterol is 1,200 tons, accounting for over half of the global capacity [3] Group 3: Financial Performance - In the first half of 2025, Garden Bio reported a revenue of 635 million yuan, with vitamin products contributing 301 million yuan and lanolin and its derivatives generating 133 million yuan [3] Group 4: Future Outlook - The approval of the new feed additive certificate is expected to create favorable conditions for the company's stable development and will be followed by compliance with relevant laws and regulations in production and sales [3]

Core Viewpoint - The production of feed-grade vitamin E in China has shown a fluctuating upward trend, with a notable decline in 2022 due to losses in the terminal breeding industry, but a gradual recovery is expected in subsequent years [1][12]. Group 1: Industry Overview - Feed-grade vitamin E is a fat-soluble vitamin essential for animal feed, known for its antioxidant properties, which enhance meat quality, growth, and survival rates [3][12]. - The production of feed-grade vitamin E primarily relies on synthetic methods due to higher efficiency and lower costs [3][12]. Group 2: Production Trends - In 2022, China's production of feed-grade vitamin E decreased by 8.3% year-on-year, primarily due to strong cost control measures in the breeding industry [1][12]. - By 2024, the production is projected to reach 63,000 tons, reflecting a year-on-year decline of 3.2% [1][12]. Group 3: Policy Support - Various policies have been introduced to promote the development of feed-grade vitamin E, including its inclusion in the encouraged foreign investment industry directory [5][7]. - The 2025 regulatory framework includes vitamin premix feed in the supervision and inspection projects, indicating a focus on quality and safety [5][7]. Group 4: Competitive Landscape - The market features a mix of international brands like DSM and domestic companies such as Zhejiang Medicine and Xinhecheng, with the latter gaining market share through innovation [14][15]. - Emerging brands are also making their mark through differentiated competition and targeted marketing strategies [14]. Group 5: Future Trends - The demand for feed-grade vitamin E is expected to rise with the ongoing development of the global livestock industry and increased awareness of animal health [19]. - Technological innovations and sustainable production methods will drive the industry's future growth, with a focus on environmental considerations [19].

Group 1 - The company Zhejiang Shengda Bio-Pharm Co., Ltd. plans to issue shares to specific investors, with the total amount of funds raised not exceeding 267.61 million yuan [1][2] - The issuance has been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The funds raised will be used for a project to produce 20,000 tons of D-isomeric ascorbic acid and its sodium salt, with a total investment of 368 million yuan [1][2] Group 2 - The issuance will involve no more than 51,356,687 shares, which is capped at 30% of the company's total share capital prior to the issuance [2][3] - The final number of shares to be issued will be determined based on the actual situation at the time of issuance [3] - Shares acquired through this issuance will be subject to a six-month lock-up period [3][4] Group 3 - The company has a plan for shareholder returns over the next three years (2023-2025), considering factors such as operational development and shareholder expectations [4] - The company will adjust the order and amount of funds allocated to projects if the actual funds raised are less than the planned investment [2][4] - The company has committed to measures to mitigate the impact of immediate return dilution on small investors [4][5] Group 4 - The company operates in the food and feed additive industry, focusing on products such as biotin and lactic acid bacteriocin [5][6] - The industry is experiencing rapid growth, but increased competition may affect profit margins [5][6] - The company has established a significant position in the market, being one of the earliest developers of biotin and biological preservatives in China [5][6]